An observational study in Cutaneous Melanoma, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by M.D. Anderson Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 108 studies in Melanoma by M.D. Anderson Cancer Center — 24 open to participants now, 41 under way, none of them phase 3. Melanoma · M.D. Anderson Cancer Center.
Among the 108 studies in Melanoma by M.D. Anderson Cancer Center, this one is the 2nd largest by planned enrollment of the 13 observational ones that give a count, is one of 6 that started in 2015, is one of 13 observational ones, reaches primary completion later than 1 of the 40 other live ones, and was the 86th registered.
3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.
Browse Melanoma studies →24 of the 108 studies in Melanoma by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
108 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 48 · Phase 2 50 · Phase 3 2
First in 1995; this study’s year is marked. 6 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 187 across 489 observational studies indexed under Melanoma.
Median enrollment 30 across the 95 interventional studies, 126 across the 13 observational. Of the 61 that completed or were terminated, 25 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
21 of the studies in Melanoma by M.D. Anderson Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04474301M.D. Anderson Cancer CenterWell-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic | 2026-12-30 |
| NCT04778449M.D. Anderson Cancer CenterQuality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma | 2026-12-31 |
| NCT04771520M.D. Anderson Cancer CenterAvapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors | 2026-12-31 |
| NCT03941756M.D. Anderson Cancer CenterLymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma | 2027-01-01 |
| NCT06237881M.D. Anderson Cancer CenterA Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors | 2027-01-01 |
Add all 21 to your calendar (.ics) → With an account.
Among the 108 studies in Melanoma by M.D. Anderson Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates the extent to which lifestyle factors including mental health, social support, diet, and exercise are associated with quality of life and melanoma patient outcomes. Knowledge gained from this study may be used to guide the design of prospective clinical trials of lifestyle interventions to improve the outcomes of melanoma patients and assist doctors in counseling their patients.
PRIMARY OBJECTIVES:
I. Collect systematic data on mental health, quality of life (QOL), social support, diet, and exercise behaviors in melanoma patients.
II. Examine whether psychosocial factors and lifestyle are associated with clinical outcomes in melanoma patients.
III. Examine the association between lifestyle and psychosocial factors and tissue and blood biomarkers in melanoma patients.
IV. Examine whether psychosocial factors and lifestyle are associated with QOL adjustment in melanoma patients.
OUTLINE:
Patients complete a maximum of 3 paper or electronic questionnaires over 30 minutes within 2 weeks of presentation to MD Anderson, new diagnosis of melanoma, and/or initiating a new treatment, within 2 weeks of first restaging, and within 2 weeks of the end of treatment. Patients may complete an additional paper or electronic dietary questionnaire over 10 minutes for 3 days (30 minutes total) or a phone-based dietary recall. Patients who start a new treatment of interest may repeat the questionnaires at the same time points. Patients' medical records are also reviewed.
Patients with melanoma, precursor lesions, and associated cutaneous pathology
Inclusion Criteria:
Patients complete a maximum of 3 paper or electronic questionnaires over 30 minutes within 2 weeks of presentation to MD Anderson, new diagnosis of melanoma, and/or initiating a new treatment, within 2 weeks of first restaging, and within 2 weeks of the end of treatment. Patients may complete an additional paper or electronic dietary questionnaire over 10 minutes for 3 days (30 minutes total) or a phone-based dietary recall. Patients who start a new treatment of interest may repeat the questionnaires at the same time points. Patients' medical records are also reviewed.
Other: Medical Chart Review · Other: Questionnaire Administration
Medical charts are reviewed
Also known as: Chart Review
Complete questionnaires
Change in depression/distress
Will be assessed using the Centers for Epidemiologic Studies - Depression. Lifetime history of Major Depressive Disorder (MDD) will be measured using the two cardinal items from the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-IV Disorder. Multivariate methods, including repeated measures analyses, will be employed to further explore the potential changes in the measures over time.
Time frame: Up to 10 years
Change in anxiety
Will be assessed using the Speilberger State/Trait Anxiety Inventory. Multivariate methods, including repeated measures analyses, will be employed to further explore the potential changes in the measures over time.
Time frame: Up to 10 years
Change in cancer-related symptoms
Will be assessed using the MD Anderson Symptom Inventory. Multivariate methods, including repeated measures analyses, will be employed to further explore the potential changes in the measures over time.
Time frame: Up to 10 years
Change in social support
Will be assessed using the 24-item Social Provisions Scale. Multivariate methods, including repeated measures analyses, will be employed to further explore the potential changes in the measures over time.
Time frame: Up to 10 years
Change in general eating habits
Will be assessed using the National Cancer Institute National Health and Nutrition Examination Survey Dietary Screener Questionnaire, and optionally, the National Institutes of Health Automated Self-Administered 24-hour.
Time frame: Up to 10 years
Change in physical activity
Will be assessed using the Godin Leisure -Time Exercise Questionnaire. Multivariate methods, including repeated measures analyses, will be employed to further explore the potential changes in the measures over time.
Time frame: Up to 10 years
Associations between mental health, social support, diet and exercise behaviors, and quality of life and demographic variables
Will be evaluated using Pearson's product moment correlation coefficients together with scatterplots where appropriate.
Time frame: Up to 10 years
Effect of diet, physical activity, depressive symptoms, distress, lifetime MDD, and social support on progression free survival
Will be evaluated using Pearson's product moment correlation coefficients together with scatterplots where appropriate.
Time frame: Up to 10 years
Effect of diet, physical activity, depressive symptoms, distress, lifetime MDD, and social support on cancer mortality
Will be evaluated using Pearson's product moment correlation coefficients together with scatterplots where appropriate.
Time frame: Up to 10 years
Response to treatment
Logistic regression models will be used to measure the association of diet, physical activity, diet, depressive symptoms, distress, lifetime MDD, and social support and response to treatment at each time point.
Time frame: Up to 10 years
Started Aug 2015 (actual). Primary completion is estimated for Dec 2026, 136 months after the start.
Of 177 non-industry observational studies under Melanoma, half reached primary completion within 178 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 320. This study's planned 136 months is below that.
Counting every sponsor, half of 236 studies reached it within 71 months; a quarter within 35 and three quarters within 248.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.